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CARDIOVASCULAR DISEASES/DISORDERS I
CV1
NONCOMPLIANCE WITH STATIN THERAPY:
LOST CLINICAL BENEFITS AND IMPLICATIONS
FOR COST-EFFECTIVENESS 
Benner JS1, Ganz DA1,Weinstein MC2, Neumann PJ2,
Glynn RJ1,Avorn J1
1Brigham and Women’s Hospital / Harvard Medical School,
Boston, MA, USA; 2Harvard School of Public Health, Boston,
MA, USA
Noncompliance with statins is common in typical patient
care settings, yet population-level beneﬁts and cost-
effectiveness have been estimated based on clinical trials,
where medication compliance is high. 
OBJECTIVES: To evaluate 1) the excess morbidity and
mortality attributable to noncompliance, and 2) the 
cost-effectiveness of statins under conditions of typical
compliance. 
METHODS: A Markov model was used to compare 
three scenarios of compliance with statin therapy (ideal,
typical, and no treatment) in a hypothetical cohort of
patients 65 to 84 years of age with a history of myocar-
dial infarction (MI). Outcomes were compared incre-
mentally among the scenarios and included lifetime risk
of reinfarction and stroke, quality-adjusted life-years
(QALYs) gained, lifetime costs in U.S. dollars, and 
cost-effectiveness (cost per QALY gained). Data for the
no treatment and ideal compliance scenarios were based
on the placebo and treatment arms of the Cholesterol And
Recurrent Events (CARE) trial, respectively. Data for the
typical compliance scenario were based on a sub-study 
of actual ﬁlled prescriptions in 1035 patients similar to
CARE participants, with effectiveness for this group
interpolated from the no treatment and ideal compliance
groups. 
RESULTS: Compared with no treatment, typical com-
pliance with statins yielded an average of 0.15 additional
QALY; ideal compliance would have gained 0.38 QALY.
For 1000 patients with typical compliance, 52 myocar-
dial infarctions and 26 strokes were attributable to non-
compliance. Compared to no treatment, the incremental
cost-effectiveness of secondary prevention with statins in
patients 65–84 years of age with typical compliance was
$14,800 per QALY gained. 
CONCLUSIONS: A typical elderly population using
statins for secondary prevention can be expected to
receive less than 40% of the potential beneﬁts of therapy.
Despite the lost clinical beneﬁts, statin therapy remains
relatively cost-effective, even when compliance is modest.
CV2
OUTCOMES AND COSTS OF ISCHEMIC
COMPLICATIONS AND BLEEDING IN PATIENTS
UNDERGOING PERCUTANEOUS CORONARY
INTERVENTIONS
Delea TE1, Plent S2, Edelsberg JS1, Oster G1
1PAI, Brookline, MA, USA; 2The Medicines Company,
Cambridge, MA, USA
OBJECTIVE: The incidence of ischemic complications
and bleeding among patients undergoing percutaneous
coronary interventions (PCIs) in clinical trials is well 
documented. Little is known about outcomes and costs
of these events in typical clinical practice however. 
METHODS: Data were obtained from a clinical and
administrative database containing information for
patients admitted to >100 geographically diverse US
acute-care hospitals (MQ-Proﬁle, Cardinal Information
Corporation, Marlborough, MA). The study sample con-
sisted all patients who underwent PCI from 7/98–6/99.
Measures included length of stay (LOS), hospital costs,
and in-hospital mortality, and were compared for patients
with vs. without ischemic complications (myocardial
infarction [MI], coronary artery bypass graft [CABG]
surgery, repeat PCI) or bleeding (major, minor) using
accelerated failure-time models for LOS and costs and
logistic regression for mortality. 
RESULTS: The sample included 5,326 PCI patients; 
mean age was 64 years; 63% were male. The incidence
of ischemic complications was 9.9% (2.9% MI, 1.4%
CABG, 5.6% repeat PCI); 11.5% experienced bleeding
(without ischemic complications) (5.9% major, 5.6%
minor). Adjusted LOS and costs in those without ischemic
complications or bleeding (n = 4,183) averaged 3.2 days
and $9,696; mortality was 1.6%. MI (n = 156), CABG
(n = 77), and repeat PCI (n = 299) patients had an
adjusted LOS of 4.1, 11.7 and 6.5 days respectively; costs
averaged $11,370, $29,470, and $18,765 (p < .001 for
all comparisons vs. no complications). Corresponding
odds ratios (ORs) for mortality were 2.8 (p = .037), 3.7
(p = .007), and 1.4 (p = .338). In patients with major
bleeding (n = 315), adjusted LOS and costs averaged 6.2
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days and $15,707 (both p < .001); corresponding ﬁgures
for those with minor bleeding (n = 296) were 4.5 days
and $11,243 (both p < .001). ORs for mortality were 2.0
for major bleeding (p = .024) and 1.2 for minor bleeding
(p = .613). 
CONCLUSION: Ischemic complications and bleeding in
patients undergoing PCI are costly and associated with
poor outcome. These events occur frequently in clinical
practice.
CV3
LONG-TERM COSTS AND CLINICAL
CONSEQUENCES OF DIFFERENT LEVELS OF 
2-HOUR POST PRANDIAL BLOOD GLUCOSE IN
NON-DIABETES PATIENTS
Palmer AJ, Roze S, Foos V, Lurati FM, Hirini S
CORE Center for Outcomes Research, Basel, Switzerland
OBJECTIVES: Recent studies (e.g. NHANES II and
DECODE) indicate that increased post-prandial blood
glucose level (PPG) is an independent risk factor for 
coronary heart disease (CHD), stroke, and cardiovascu-
lar disease (CVD) death. A modeling study was per-
formed to combine best available data with costs of CVD
complications to project possible long-term clinical and
cost outcomes for non-diabetic people with different
baseline PPGs. 
METHODS: Risks of CHD, stroke, and CVD death
derived from Framingham formulae were combined with
published 2-hour PPG-dependent hazard ratios for 
incident CHD, stroke, and CVD death to calculate CVD
events and subsequent changes in life expectancy (LE)
dependent on different baseline PPG levels for a typical
non-diabetic population. Direct costs of CVD complica-
tions were projected over 50 years using a Markov model.
A US Medicare payer perspective was taken. Only direct
costs were included. Discounted rates of 3% p.a. were
used. Sensitivity analysis was performed to identify 
parameters with the greatest impact on outcomes. 
RESULTS: A typical population of non-diabetic patients
with baseline age of 60 years and 2-hour PPG levels of
14.6, 12.6, 10.6, or 8.6mmol/l were calculated to have
LE of 19.93, 21.23, 22.25, and 23.02 years respectively.
Lifetime costs per patient due to CVD complications were
calculated to be $20,186, $19,417, $18,366, $17,151
respectively. Parameters with the greatest impact on 
outcomes were baseline age of the population, PPG 
levels, and other CVD risk factors including blood 
pressure and lipids. 
CONCLUSIONS: Lower 2-hPPG levels are associated
with higher life expectancy and reduced costs due to 
cardiovascular complications. Considering the important
impact of PPG and other modiﬁable CVD risk factors, a
multifactorial approach to addressing these risk factors 
is recommended. Interventions aimed at improving PPG
levels could be cost-effective, due to the additional costs
of interventions being offset by reduced costs of CVD
complications.
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CORRELATION BETWEEN NEW YORK HEART
ASSOCIATION CLASSIFICATION AND PATIENT-
REPORTED OUTCOMES
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Heart failure (HF) affects nearly 5 million Americans with
a 5-year mortality rate of 50%. There is limited infor-
mation on the relationship between patient-reported out-
comes (e.g., utilities, quality of life) and New York Heart
Association (NYHA) classiﬁcation. 
OBJECTIVE: The objective of this study was to compare
the correlation between utilities, QOL scores and NYHA
class. 
METHODS: One hundred-two ambulatory HF patients
provided utilities using the Rating Scale (RS), Time-
Trade-Off (TTO) and Standard Gamble (SG) methods
and QOL using the Medical Outcomes Study Short-Form
36 (SF-36) and the Minnesota Living with Heart Failure
Questionnaire (MLHFQ). NYHA class was extracted
from patient charts. Data were analyzed using Pearson’s
Correlation Coefﬁcients and ANCOVA. 
RESULTS: There were 11 Class I, 40 Class II, 34 Class
III, and 17 Class IV HF patients. Mean age varied by 
class (47.5, 55.3, 51.8, and 55.0 years, respectively).
More patients were female (62.0% overall), except Class
I (36.4% female). Mean physical component summary
scores (PCS) from the SF-36 were signiﬁcantly different
but mental component summary scores did not vary by
NYHA class. Mean total MLHFQ scores were 20.2, 46.4,
61.9, and 80.8, respectively. Mean utility scores from the
RS were 0.68, 0.60, 0.47, and 0.40; from the SG were
0.90, 0.85, 0.71, and 0.67; and from the TTO were 0.87,
0.88, 0.68, and 0.62, respectively. All means were
adjusted for age and gender. The PCS, MLHFQ, and
utility measures showed a consistent monotonic relation-
ship with increasing HF class. Correlation between utility
measures and the PCS and MLHFQ were highly signiﬁ-
cant (PCS r = 0.30 to 0.47; and MLHFQ r = -0.53 to 
-0.33 for the RS, SG, and TTO; p < 0.001). 
CONCLUSIONS: Results support prior belief that
patient-reported outcomes worsen with HF progression.
QOL and utility measures may assist clinicians quantify-
ing the impact of HF on patients’ well-being.
